Related Experiment Videos
Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis
Abstract:
This paper reports our experience in monitoring gentamicin therapy during the treatment of 68 episodes of serious Gram-negative sepsis in 65 hospital patients. Most of the patients had major underlying disease. Of those who were adequately treated (peak serum concentrations of 5 mug/ml or more in 72 hours for septicaemia, urinary tract infection, and wound infection; and 8 mug/ml or more at some time during the course of treatment for pneumonia) 84% (46 out of 55) were cured. These serum concentrations could be achieved only by starting with a regimen of 5 mg/kg/day in three divided doses in all adult patients, subsequent dosage being determined by the results of rapid serum assay. The incidence of nephrotoxicity and symptomatic ototoxicity was no greater than in previous series. The main reason for assaying serum gentamicin is to ensure that an adequate dosage is achieved as soon as possible. In patients with impaired renal function or receiving prolonged high dosage assays also serve to guard against an excessive accumulation of gentamicin and an increased risk of toxicity.
Insights
Monitoring gentamicin therapy in serious Gram-negative sepsis is crucial. Adequate serum concentrations, achieved through tailored dosing and assays, led to an 84% cure rate with no increased toxicity.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Therapeutics
Background:
- Serious Gram-negative sepsis poses significant treatment challenges.
- Gentamicin is a key antibiotic for managing Gram-negative infections.
- Effective therapeutic drug monitoring is essential for optimizing gentamicin efficacy and safety.
Purpose of the Study:
- To evaluate the impact of gentamicin therapy monitoring on treatment outcomes in patients with serious Gram-negative sepsis.
- To determine the relationship between serum gentamicin concentrations and clinical cure rates.
- To assess the incidence of nephrotoxicity and ototoxicity associated with monitored gentamicin therapy.
Main Methods:
- Retrospective analysis of 68 episodes of Gram-negative sepsis in 65 hospitalized patients.
- Therapeutic drug monitoring of serum gentamicin concentrations.
- Dosage adjustments based on rapid serum assay results.
- Correlation of peak serum concentrations with clinical cure rates.
Main Results:
- An 84% cure rate (46/55) was observed in patients achieving adequate serum gentamicin concentrations (≥5 µg/ml for sepsis/UTI/wound, ≥8 µg/ml for pneumonia).
- Initial dosing regimen of 5 mg/kg/day divided into three doses was effective in achieving target concentrations in adults.
- Incidence of nephrotoxicity and ototoxicity was comparable to previous studies without therapeutic drug monitoring.
Conclusions:
- Therapeutic drug monitoring of gentamicin is vital for achieving effective serum concentrations and improving cure rates in serious Gram-negative sepsis.
- Individualized dosing guided by serum assays ensures therapeutic efficacy while minimizing toxicity risks.
- Monitoring is particularly important in patients with renal impairment or those receiving prolonged high-dose therapy.